Oncology Specialists, S.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2010-03-02
Last Posted Date
2014-07-16
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
11
Registration Number
NCT01078922
Locations
🇺🇸

Oncology Specialists, S.C., Park Ridge, Illinois, United States

🇺🇸

Oncology Specialists, S.C, Niles, Illinois, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-06-11
Last Posted Date
2014-06-30
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
21
Registration Number
NCT00919035
Locations
🇺🇸

Oncology Specialists, S.C., Park Ridge, Illinois, United States

🇺🇸

Oncology Specialists, SC, Niles, Illinois, United States

Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era

Completed
Conditions
First Posted Date
2009-05-15
Last Posted Date
2014-07-01
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
50
Registration Number
NCT00902434

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-04-07
Last Posted Date
2014-03-28
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
32
Registration Number
NCT00654186
Locations
🇺🇸

Oncology Specialists, S.C, Park Ridge, Illinois, United States

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2007-01-19
Last Posted Date
2014-07-21
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
17
Registration Number
NCT00424385
Locations
🇺🇸

Oncology Specialists, S.C, Park Ridge, Illinois, United States

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-12-21
Last Posted Date
2014-04-07
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
22
Registration Number
NCT00414388
Locations
🇺🇸

Onocology Specialists, S.C, Niles, Illinois, United States

🇺🇸

Oncology Specialists, S.C, Park Ridge, Illinois, United States

VELCADE,Rituximab,Cyclophosphamide and Decadron

First Posted Date
2006-12-20
Last Posted Date
2018-09-19
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
12
Registration Number
NCT00413959
Locations
🇺🇸

Onocology Specialists, S.C, Niles, Illinois, United States

🇺🇸

Oncology Specialists, S.C, Park Ridge, Illinois, United States

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-01-10
Last Posted Date
2019-03-28
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
15
Registration Number
NCT00274287
Locations
🇺🇸

Oncology Specialists, SC, Park Ridge, Illinois, United States

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-01-04
Last Posted Date
2018-06-27
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
29
Registration Number
NCT00272038
Locations
🇺🇸

Oncology Specialists, SC, Park Ridge, Illinois, United States

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2005-09-12
Last Posted Date
2017-11-29
Lead Sponsor
Oncology Specialists, S.C.
Target Recruit Count
33
Registration Number
NCT00156013
Locations
🇺🇸

Oncology Specialists, SC, Park Ridge, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath